Vaccines for the World
51 results
of 5
Contributor: Gary Hutchinson
Posted: 29/06/2016
Gary Hutchinson
Clinical trial material (CTM) or investigational medicinal products (IMP) are an important part of the early stages of the life science supply chain. As trials are being run on a global scale, in markets with less than ideal infrastructure, there is a dire need for companies to work with specialized cold chain experts to engineer and design innovative distribution processes.
Cold chain failure may lead to: the patient being administered an unsafe product; liability based on compliance infractions; inconsistent data results; or an entire shipment’s product integrity could be rejected by the quality department, resulting in costly delays. Full Content »
Contributor: Tony Hitchcock
Posted: 16/05/2016
Tony Hitchcock
Earlier this year I was fortunate enough to attend the Disposable Solutions meeting in Munich. A common theme of discussions was the on-going debates around the issues of leachable and extractables and the associated testing standards. This is a topic that has been debated for as long as I have been attending meetings on single use systems, and still seems to be a long way from a consensus between various end users and manufacturing bodies on how to address this issue. Full Content »
Contributor: Cold Chain IQ Surveys
Posted: 04/05/2016
Cold Chain IQ Surveys
Cold Chain IQ would like to invite you to take part in this short industry survey.

The survey will take 10 minutes to complete and as a thank you, all participants who complete the survey can choose to be entered into a PRIZE DRAW for a complimentary pass to Temperature Controlled Logistics 2017 in London- With the event's usual entry fee standing at £1499. Full Content »
Contributor: Miss Chanice Henry
Posted: 04/05/2016
Miss Chanice Henry
China’s State Council has passed an amendment on vaccine regulations just weeks after the launch of an investigation into incorrectly handled vaccines took place, in ‘a case that shook the country’. Full Content »
Contributor: Cathy Roberson
Posted: 27/04/2016
Cathy
For healthcare professionals, the use of drones has huge benefits in particular the ability to reach remote areas that lack proper infrastructure to deliver lifesaving drugs and other necessities. Many tests are underway to determine its viability but as one can imagine, it is under much government scrutiny and regulators in many countries are working with the industry to develop requirements for the delivery and flying of drones. Full Content »
Contributor: Chanice Henry
Posted: 08/03/2016
Chanice Henry
Last month saw Johnson & Johnson win the Best Temperature Controlled Logistics Project Award at the 2016 Temperature Controlled Logistics Awards. This was in relation to organising the supply chain through Sierra Leone for the shipment and storage of an Ebola vaccine. Full Content »
Contributor: Miss Chanice Henry
Posted: 01/12/2015
Miss Chanice Henry
Reports have recently emerged that spacecraft technology is one of the latest breakthroughs to advance the cold chain market. Full Content »
Contributor: Miss Chanice Henry
Posted: 06/10/2015
Miss Chanice Henry
Last month, the United Nations Food and Agriculture Organisation (FAO) alongside the Ministry of Livestock and Fisheries Industry opened Juba’s revitalised core cold chain. The new cold chain looks to safeguard the integrity of livestock vaccines. Full Content »
Contributor: Cold Chain IQ
Posted: 08/06/2015
Cold Chain IQ
A late-stage biopharmaceutical company developing products in inflammation, oncology and biodefense, has recently published data demonstrating a heat stable vaccine formulation of a human papillomavirus (HPV) vaccine. Full Content »
Posted: 28/04/2015
Getting Essential Medicines to Customers: Investment in Supply Chains
Recently, the members of the Getting Health Products to People: Alliance for Health Logistics—that seeks to improve health product availability throughout Latin America and the Caribbean (LAC)—produced an infographic for health policymakers. Using this new material, the Alliance members will jointly encourage countries to invest—not only in procuring essential medicines—but also in the public health supply chains that deliver these products to the people who need them.

The graphic demonstrates that by committing between .05-.33 cents to supply chains for every US$ dollar invested in products, countries can strengthen their health programs, better serve their customers, and help meet their development goals. Full Content »
Posted: 28/04/2015
Predictions 2035: The Role of Performance-Based Financing in Future Supply Chains in Developing Countries
Predictions 2035: The Role of Performance-Based Financing in Future Supply Chains in Developing Countries begins by summarising the context for global health in 2035 as predicted by the recent Lancet Commissions report, "Global health 2035: a world converging within a generation." It then explores the project’s own forecasts for the future of public health supply chains while identifying implications for performance-based financing schemes under the functions of financing, supply chain design, information systems, storage and distribution, human resources, governance, and accountability. Full Content »
51 results
of 5
Posted: 05/08/2014
Cool Chain 2015 - Where the Industry Meets to Shape its Future
With over 500 participants from hundreds of different pharmaceutical manufacturers, leading solution providers and cold chain logistics experts, Cool Chain & Temperature Controlled Logistics Europe 2015 is truly an event not-to-be-missed! Full Video »
Contributor: Andrea Charles
Posted: 23/10/2011
Cold Chain podcast
The 2 million vaccine preventable deaths do not occur for lack of vaccines, but because of inadequate distribution. In this interview Harvey Rubin, Director of Strategic Threat Analysis and Response at the University of Pennsylvania, speaks to Andrea Charles from Pharma IQ, about the Our Energy for Health Project whose proposal is to use the Full Podcast »
Contributor: Gary Hutchinson
Posted: 29/06/2016
Gary Hutchinson
Clinical trial material (CTM) or investigational medicinal products (IMP) are an important part of the early stages of the life science supply chain. As trials are being run on a global scale, in markets with less than ideal infrastructure, there is a dire need for companies to work with specialized cold chain experts to engineer and design innovative distribution processes. Cold chain failure may lead to: the patient being administered an unsafe product; liability based on compliance infractions; inconsistent data results; or an entire shipment’s product integrity could be rejected by the quality department, resulting in costly delays. Full Column »
Posted: 28/04/2015
Getting Essential Medicines to Customers: Investment in Supply Chains
Recently, the members of the Getting Health Products to People: Alliance for Health Logistics—that seeks to improve health product availability throughout Latin America and the Caribbean (LAC)—produced an infographic for health policymakers. Using this new material, the Alliance members will jointly encourage countries to invest—not only in procuring essential medicines—but also in the public health supply chains that deliver these products to the people who need them.

The graphic demonstrates that by committing between .05-.33 cents to supply chains for every US$ dollar invested in products, countries can strengthen their health programs, better serve their customers, and help meet their development goals. Full Whitepaper »